A single neurotoxic dose of methamphetamine induces a long-lasting depressive-like behaviour in mice

Neurotoxicity Research

Volumn 25, Issue 3, 2014, Pages 295-304

  Silva, Carlos D ^a   Neves, Ana F ^a   Dias, Ana I ^a   Freitas, Hugo J ^a   Mendes, Sheena M ^a   Pita, Inês ^a   Viana, Sofia D ^a   De Oliveira, Paulo A ^b   Cunha, Rodrigo A ^c   Fontes Ribeiro, Carlos A ^a   Prediger, Rui D ^b   Pereira, Frederico C ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Depression; Frontal cortex; Methamphetamine; Monoaminergic disruption; Striatum; Tail suspension test

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CELL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; HOMOVANILLIC ACID; METHAMPHETAMINE; SEROTONIN; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOPAMINERGIC TRANSMISSION; FORCED SWIM TEST; FRONTAL CORTEX; LATENT PERIOD; MALE; MENTAL TASK; MORRIS WATER MAZE TEST; MOUSE; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; TAIL SUSPENSION TEST; TASK PERFORMANCE;

ANIMALS; ASTROCYTES; CORPUS STRIATUM; DEPRESSIVE DISORDER; DOPAMINE; ESCAPE REACTION; FRONTAL LOBE; LOCOMOTION; MALE; MAZE LEARNING; MEMORY; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; NEUROTOXICITY SYNDROMES; SEROTONIN; SWIMMING; TIME FACTORS;

EID: 84896056748     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-013-9423-2     Document Type: Article

References (69)

1. Agostinho P, Cunha RA, Oliveira C (2010) Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 16:2766-2778
2. Allaman I, Bélanger M, Magistretti PJ (2011) Astrocyte-neuron metabolic relationships: for better and for worse. Trends Neurosci 34:76-87
3. Banasr M, Duman RS (2008) Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 64:863-870
4. Berton O, Hahn CG, Thase ME (2012) Are we getting closer to valid translational models for major depression? Science 338:75-79
5. Bora E, Harrison BJ, Davey CG, Yücel M, Pantelis C (2012) Meta-analysis of volumetric abnormalities in cortico-striatal-pallidal-thalamic circuits in major depressive disorder. Psychol Med 42:671-681
6. Brière FN, Fallu J-S, Janosz M, Pagani LS (2012) Prospective associations between meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms in secondary school students. J Epidemiol Community Health 66:990-994
7. Cappon GD, Pu C, Vorhees CV (2000) Time-course of methamphetamine-induced neurotoxicity in rat caudate-putamen after single-dose treatment. Brain Res 863:106-111 (Pubitemid 30201589)
8. Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos MDL (2012) Toxicity of amphetamines: an update. Arch Toxicol 86:1167-1231
9. Cryan JF, Hoyer D, Markou A (2003) Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry 54:49-58 (Pubitemid 36776723)
10. Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571-625 (Pubitemid 40755457)
11. Darke S, Kaye S, McKetin R, Duflou J (2008) Major physical and psychological harms of methamphetamine use. Drug Alcohol Rev 27:253-262
12. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 36:1-22 (Pubitemid 32763126)
13. Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, Mathis C (1999) PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 21:694-709
14. Dzirasa K, Covington HE 3rd (2012) Increasing the validity of experimental models for depression. Ann N Y Acad Sci 1265:36-45
15. El Yacoubi M, Vaugeois JM (2007) Genetic rodent models of depression. Curr Opin Pharmacol 7:3-7 (Pubitemid 46238040)
16. European Monitoring Centre for Drugs and Drug Addiction (2012) Annual report 2012: the state of the drugs problem in Europe. Publications Office of the European Union, Luxembourg
17. Fanselow MS, Dong HW (2010) Are the dorsal and ventral hippocampus functionally distinct structures? Neuron 65:7-19
18. Friedman SD, Castañeda E, Hodge GK (1998) Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 61:35-44 (Pubitemid 28477482)
19. Glasner-Edwards S, Marinelli-Casey P, Hillhouse M, Ang A, Mooney LJ, Rawson R (2009) Depression among methamphetamine users. J Nerv Ment Dis 197:225-231
20. Gonçalves J, Baptista S, Martins T, Milhazes N, Borges F, Ribeiro CF, Malva JO, Silva AP (2010) Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur J Neurosci 31:315-326
21. Gouzoulis-Mayfrank E, Daumann J (2009) Neurotoxicity of drugs of abuse-the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues Clin Neurosci 11:305-317
22. Grace CE, Schaefer TL, Herring NR, Graham DL, Matthew R, Gudelsky GA, Williams MT, Vorhees CV (2010) Effect of a neurotoxic dose regimen of (+)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6 mice. Neurotoxicol Teratol 32:346-355
23. Herring NR, Gudelsky GA, Vorhees CV, Williams MT (2010) (+)-Methamphetamine-induced monoamine reductions and impaired egocentric learning in adrenalectomized rats is independent of hyperthermia. Synapse 64:773-785
24. Holmes PV (2003) Rodent models of depression: reexamining validity without anthropomorphic inference. Crit Rev Neurobiol 15:143-174
25. Homer BD, Solomon TM, Moeller RW, Mascia A, DeRaleau L, Halkitis PN (2008) Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull 134:301-310
26. Hotchkiss AJ, Morgan ME, Gibb JW (1979) The long-term effects of multiple doses of methamphetamine on neostriatal tryptophan hydroxylase, tyrosine hydroxylase, choline acetyltransferase and glutamate decarboxylase activities. Life Sci 25:1373-1378 (Pubitemid 10191884)
27. Iijima M, Koike H, Chaki S (2013) Effect of an mGlu2/3 receptor antagonist on depressive behavior induced by withdrawal from chronic treatment with methamphetamine. Behav Brain Res 246:24-28
28. Imam SZ, Ali SF (2001) Aging increases the susceptibility to methamphetamine-induced dopaminergic neurotoxicity in rats: correlation with peroxynitrite production and hyperthermia. J Neurochem 78:952-959 (Pubitemid 32823144)
29. Jang C-G, Whitfield T, Schulteis G, Koob GF, Wee S (2013) A dysphoric-like state during early withdrawal from extended access to methamphetamine self-administration in rats. Psychopharmacology 225:753-763
30. Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J, Galloway GP, Koeppe RA, Kilbourn MR, Robbins T, Schuster CR (2006) Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology 185:327-338
31. Kimelberg HK, Nedergaard M (2010) Functions of astrocytes and their potential as therapeutic targets. Neurotherapeutics 7:338-353
32. Kish SJ, Fitzmaurice PS, Boileau I, Schmunk GA, Ang L-C, Furukawa Y, Chang L-J, Wickham DJ, Sherwin A, Tong J (2009) Brain serotonin transporter in human methamphetamine users. Psychopharmacology 202:649-661
33. Kitamura O, Tokunaga I, Gotohda T, Kubo S (2007) Immunohistochemical investigation of dopaminergic terminal markers and caspase-3 activation in the striatum of human methamphetamine users. Int J Leg Med 121:163-168 (Pubitemid 46866579)
34. Kitamura O, Takeichi T, Wang EL, Tokunaga I, Ishigami A, Kubo S (2010) Microglial and astrocytic changes in the striatum of methamphetamine abusers. Leg Med (Tokyo) 12:57-62
35. Krasnova IN, Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60:379-407
36. Krishnan V, Nestler EJ (2010) Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry 167:1305-1320
37. Lee S, Jeong J, Kwak Y, Park SK (2010) Depression research: where are we now? Mol Brain 3:8
38. Lemke M, Fuchs G, Gemende I, Herting B, Oehlwein C, Reichmann H, Rieke J, Volkmann J (2004) Depression and Parkinson's disease. J Neurol 251:24-27
39. London ED, Simon SL, Berman SM, Mandelkern MA, Lichtman AM, Bramen J, Shinn AK, Miotto K, Learn J, Dong Y, Matochik JA, Kurian V, Newton T, Woods R, Rawson R, Ling W (2004) Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry 61:73-84 (Pubitemid 38044643)
40. Miller DB, O'Callaghan JP (2003) Elevated environmental temperature and methamphetamine neurotoxicity. Environ Res 92:48-53 (Pubitemid 36438558)
41. Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ, Aiken SS, Wickham DJ, Kish SJ (2004) Why is Parkinsonism not a feature of human methamphetamine users? Brain 127:363-370 (Pubitemid 38160321)
42. Nestler EJ, Carlezon WA (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151-1159 (Pubitemid 44192421)
43. Nutt DJ, Baldwin DS, Clayton AH, Elgie R, Lecrubier Y, Montejo AL, Papakostas GI, Souery D, Trivedi MH, Tylee A (2006) Consensus statement and research needs: the role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 67(Suppl 6):46-49 (Pubitemid 44078114)
44. O'Callaghan J, Miller D (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751 (Pubitemid 24271391)
45. O'Callaghan JP, Sriram K, Miller DB (2008) Defining " neuroinflammation". Ann N Y Acad Sci 1139:318-330
46. Panenka WJ, Procyshyn RM, Lecomte T, Macewan GW, Flynn SW, Honer WG, Barr AM (2012) Methamphetamine use: a comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend 129:1-13
47. Páv M, Kovárů H, Fiserová A, Havrdová E, Lisá V (2008) Neurobiological aspects of depressive disorder and antidepressant treatment: role of glia. Physiol Res 57:151-164
48. Pekny M, Nilsson M (2005) Astrocyte activation and reactive gliosis. Glia 50:427-434 (Pubitemid 40780846)
49. Pereira FC, Lourenço ES, Borges F, Morgadinho T, Ribeiro CF, Macedo TR, Ali SF (2006) Single or multiple injections of methamphetamine increased dopamine turnover but did not decrease tyrosine hydroxylase levels or cleave caspase-3 in caudate-putamen. Synapse 60:185-193 (Pubitemid 44036713)
50. Pereira FC, Cunha-Oliveira T, Viana SD, Travassos AS, Nunes S, Silva C, Prediger RD, Rego AC, Ali SF, Ribeiro CAF (2012) Disruption of striatal glutamatergic/GABAergic homeostasis following acute methamphetamine in mice. Neurotoxicol Teratol 34:522-529
51. Prediger RDS, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN (2006) The risk is in the air: intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 202:391-403 (Pubitemid 44692682)
52. Rajkowska G, Stockmeier CA (2013) Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 14:1225-1236
53. Rawson RA, Huber A, Brethen P, Obert J, Gulati V, Shoptaw S, Ling W (2002) Status of methamphetamine users 2-5 years after outpatient treatment. J Addict Dis 21:107-119 (Pubitemid 35203857)
54. Renoir T, Païzanis E, El Yacoubi M, Saurini F, Hanoun N, Melfort M, Lesch KP, Hamon M, Lanfumey L (2008) Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wild-type mice. Int J Neuropsychopharmacol 11:1149-1162
55. Rowe DC, Stever C, Gard JM, Cleveland HH, Sanders ML, Abramowitz A, Kozol ST, Mohr JH, Sherman SL, Waldman ID (1998) The relation of the dopamine transporter gene (DAT1) to symptoms of internalizing disorders in children. Behav Gen 28:215-225 (Pubitemid 28313460)
56. Sailasuta N, Abulseoud O, Harris KC, Ross BD (2010) Glial dysfunction in abstinent methamphetamine abusers. J Cereb Blood Flow Metab 30:950-960
57. Sanacora G, Banasr M (2013) From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry 73:1172-1179
58. Savitz JB, Drevets WC (2012) Neuroreceptor imaging in depression. Neurobiol Dis 52:49-65
59. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17:275-297 (Pubitemid 47498174)
60. Segman RH, Shalev AY (2003) Genetics of posttraumatic stress disorder. CNS Spectr 8:693-698 (Pubitemid 38418989)
61. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, Okada H, Minabe Y, Suzuki K, Iwata Y, Tsuchiya KJ, Tsukada H, Iyo M, Mori N (2006) Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 63:90-100 (Pubitemid 43037473)
62. Semple SJ, Grant I, Patterson TL (2005) Negative self-perceptions and sexual risk behavior among heterosexual methamphetamine users. Subst Use Misuse 40:1797-1810 (Pubitemid 41546465)
63. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85 (Pubitemid 16258399)
64. Steru L, Chermat R, Thierry B, Simon P (1985) A new method for screening antidepressants in mice. Psychopharmacology 85:367-370
65. Tulloch I, Afanador L, Mexhitaj I, Ghazaryan N, Garzagongora AG, Angulo JA (2011) A single high dose of methamphetamine induces apoptotic and necrotic striatal cell loss lasting up to 3 months in mice. Neuroscience 193:162-169
66. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703 (Pubitemid 26191961)
67. Xu W, Zhu JPQ, Angulo JA (2005) Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. Synapse 58:110-121 (Pubitemid 41443747)
68. Zhu JP, Xu W, Angulo JA (2005) Disparity in the temporal appearance of methamphetamine-induced apoptosis and depletion of dopamine terminal markers in the striatum of mice. Brain Res 1049:171-181 (Pubitemid 41072933)
69. Zorick T, Nestor L, Miotto K, Sugar C, Hellemann G, Scanlon G, Rawson R, London ED (2010) Withdrawal symptoms in abstinent methamphetamine-dependent subjects. Addiction 105:1809-1818